Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Neuroimaging in Parkinson's disease.

Literature DB >> 15717025

Neuroimaging in Parkinson's disease.

Abstract

In this review, the potential role of positron emission tomography and single photon emission computed tomography as biological markers for diagnosing and following the progression of Parkinson's disease (PD) is discussed. Their value for assessing the efficacy of putative neuroprotective agents in PD and for revealing the pharmacological changes underlying the symptomatology and complications of this disorder is also considered. It is concluded that in the future functional imaging will provide a valuable adjunct to clinical assessment when judging the efficacy of putative neuroprotective approaches to PD.

Entities: Disease

Mesh：

Year: 2004 PMID： 15717025 PMCID： PMC534937 DOI： 10.1602/neurorx.1.2.243

Source DB: PubMed Journal: NeuroRx ISSN： 1545-5343

83 in total

1. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease.

Authors: G K Wenning; P Odin; P Morrish; S Rehncrona; H Widner; P Brundin; J C Rothwell; R Brown; B Gustavii; P Hagell; M Jahanshahi; G Sawle; A Björklund; D J Brooks; C D Marsden; N P Quinn; O Lindvall
Journal: Ann Neurol Date: 1997-07 Impact factor: 10.422

Review 2. The genetics of Parkinson's disease: a reconsideration.

Authors: L I Golbe
Journal: Neurology Date: 1990-10 Impact factor: 9.910

3. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease.

Authors: J H Kordower; T B Freeman; E Y Chen; E J Mufson; P R Sanberg; R A Hauser; B Snow; C W Olanow
Journal: Mov Disord Date: 1998-05 Impact factor: 10.338

4. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors: P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal: J Neurol Neurosurg Psychiatry Date: 1998-03 Impact factor: 10.154

5. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

Authors: S J Kish; K Shannak; O Hornykiewicz
Journal: N Engl J Med Date: 1988-04-07 Impact factor: 91.245

6. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.

Authors: N Turjanski; A J Lees; D J Brooks
Journal: Neurology Date: 1997-09 Impact factor: 9.910

7. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold.

Authors: M Guttman; J Burkholder; S J Kish; D Hussey; A Wilson; J DaSilva; S Houle
Journal: Neurology Date: 1997-06 Impact factor: 9.910

8. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease.

Authors: U K Rinne; A Laihinen; J O Rinne; K Någren; J Bergman; U Ruotsalainen
Journal: Mov Disord Date: 1990 Impact factor: 10.338

9. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.

Authors: P Piccini; R A Weeks; D J Brooks
Journal: Ann Neurol Date: 1997-11 Impact factor: 10.422

10. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains.

Authors: P L McGeer; S Itagaki; B E Boyes; E G McGeer
Journal: Neurology Date: 1988-08 Impact factor: 9.910

21 in total

Review 1. Imaging in cell-based therapy for neurodegenerative diseases.

Authors: Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal: Eur J Nucl Med Mol Imaging Date: 2005-12 Impact factor: 9.236

Review 2. Human gene therapy and imaging in neurological diseases.

Authors: Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal: Eur J Nucl Med Mol Imaging Date: 2005-12 Impact factor: 9.236

3. Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors: Jeffrey S Stehouwer; Mark M Goodman
Journal: PET Clin Date: 2009-01

Review 4. Guided delivery of adeno-associated viral vectors into the primate brain.

Authors: Ernesto A Salegio; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof Bankiewicz
Journal: Adv Drug Deliv Rev Date: 2011-10-20 Impact factor: 15.470

Review 5. MicroPET investigation of chronic long-term neurotoxicity from heavy ion irradiation.

Authors: Onarae Rice; Sandra Saintvictor; Michael Michaelides; Panayotis Thanos; Samuel John Gatley
Journal: AAPS J Date: 2006-08-04 Impact factor: 4.009

6. Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease.

Authors: Jeffrey S Schweitzer; Bin Song; Todd M Herrington; Tae-Yoon Park; Nayeon Lee; Sanghyeok Ko; Jeha Jeon; Young Cha; Kyungsang Kim; Quanzheng Li; Claire Henchcliffe; Michael Kaplitt; Carolyn Neff; Otto Rapalino; Hyemyung Seo; In-Hee Lee; Jisun Kim; Taewoo Kim; Gregory A Petsko; Jerome Ritz; Bruce M Cohen; Sek-Won Kong; Pierre Leblanc; Bob S Carter; Kwang-Soo Kim
Journal: N Engl J Med Date: 2020-05-14 Impact factor: 91.245

10. Influence of O-methylated metabolite penetrating the blood-brain barrier to estimation of dopamine synthesis capacity in human L-[β-(11)C]DOPA PET.

Authors: Keisuke Matsubara; Yoko Ikoma; Maki Okada; Masanobu Ibaraki; Tetsuya Suhara; Toshibumi Kinoshita; Hiroshi Ito
Journal: J Cereb Blood Flow Metab Date: 2013-11-06 Impact factor: 6.200